Published in J Mol Diagn on June 26, 2013
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol (2015) 4.97
Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing. Virchows Arch (2014) 1.93
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia (2015) 1.44
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget (2016) 1.41
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica (2013) 1.37
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res (2015) 1.29
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist (2014) 1.24
Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem (2015) 1.16
False positives in multiplex PCR-based next-generation sequencing have unique signatures. J Mol Diagn (2014) 1.16
Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer (2014) 1.08
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol (2014) 1.07
Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges. Cancers (Basel) (2015) 1.01
Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget (2015) 1.01
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer (2014) 0.98
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PLoS One (2014) 0.97
Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin (2015) 0.97
Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. PLoS One (2014) 0.96
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Cold Spring Harb Mol Case Stud (2015) 0.96
Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. BMC Med Genomics (2014) 0.95
Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. Br J Cancer (2015) 0.94
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res (2015) 0.94
Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors. Exp Mol Pathol (2015) 0.92
Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers. PLoS One (2015) 0.90
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. PLoS One (2014) 0.89
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. Oncotarget (2015) 0.88
Highly sensitive amplicon-based transcript quantification by semiconductor sequencing. BMC Genomics (2014) 0.87
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. J Mol Diagn (2016) 0.87
Implementation of Cloud based next generation sequencing data analysis in a clinical laboratory. BMC Res Notes (2014) 0.87
Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma. Oncotarget (2015) 0.86
Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. Cancers (Basel) (2015) 0.85
Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations. J Mol Diagn (2015) 0.85
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer (2015) 0.84
Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing. J Mol Diagn (2015) 0.83
Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA. PLoS One (2015) 0.83
Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR. BMJ Open (2016) 0.83
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. J Transl Med (2014) 0.82
Comparison of custom capture for targeted next-generation DNA sequencing. J Mol Diagn (2015) 0.81
Advancing clinical oncology through genome biology and technology. Genome Biol (2014) 0.81
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies. J Vis Exp (2016) 0.81
Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi. J Invest Dermatol (2016) 0.80
Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer (2015) 0.80
Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel. PLoS One (2016) 0.79
Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. Mol Cancer (2016) 0.79
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer (2016) 0.79
Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays. J Mol Diagn (2016) 0.78
Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2. BMC Cancer (2016) 0.78
Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle. Head Neck Pathol (2014) 0.78
Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer (2015) 0.78
Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing. PLoS One (2015) 0.78
Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors. PLoS One (2016) 0.78
Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing. Onco Targets Ther (2015) 0.77
Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecol Oncol (2016) 0.77
Reference standards for next-generation sequencing. Nat Rev Genet (2017) 0.77
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol (2015) 0.77
Isolating Viral and Host RNA Sequences from Archival Material and Production of cDNA Libraries for High-Throughput DNA Sequencing. Curr Protoc Microbiol (2015) 0.77
Validation of multiple single nucleotide variation calls by additional exome analysis with a semiconductor sequencer to supplement data of whole-genome sequencing of a human population. BMC Genomics (2014) 0.77
Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma. Cancer Cytopathol (2015) 0.77
Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med (2016) 0.76
Integrative analysis of methylome and transcriptome in human blood identifies extensive sex- and immune cell-specific differentially methylated regions. Epigenetics (2015) 0.76
Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. Oncotarget (2016) 0.76
Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. J Cancer Res Clin Oncol (2015) 0.76
Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response. Endocrinol Diabetes Metab Case Rep (2016) 0.76
Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis. Genome Med (2015) 0.76
Uncommon nucleotide excision repair phenotypes revealed by targeted high-throughput sequencing. Orphanet J Rare Dis (2016) 0.76
Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. Cancer (2016) 0.75
Exploring Genetic Diversity in Plants Using High-Throughput Sequencing Techniques. Curr Genomics (2016) 0.75
Enrichment and single-cell analysis of circulating tumor cells. Chem Sci (2016) 0.75
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci (2017) 0.75
Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget (2016) 0.75
A Genomic Study of DNA Alteration Events Caused by Ionizing Radiation in Human Embryonic Stem Cells via Next-Generation Sequencing. Stem Cells Int (2015) 0.75
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget (2016) 0.75
Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing. PLoS One (2016) 0.75
Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing. Diagn Pathol (2015) 0.75
Statistical method to compare massive parallel sequencing pipelines. BMC Bioinformatics (2017) 0.75
Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. Biomed Res Int (2016) 0.75
Comparative mutational landscape analysis of patient-derived tumour xenografts. Br J Cancer (2017) 0.75
High-Throughput Resequencing of Maize Landraces at Genomic Regions Associated with Flowering Time. PLoS One (2017) 0.75
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn (2017) 0.75
StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors. Cancer Med (2017) 0.75
A somatic reference standard for cancer genome sequencing. Sci Rep (2016) 0.75
Next generation sequencing of the nidus of early (adenosquamous proliferation rich) radial sclerosing lesions of the breast reveals evidence for a neoplastic precursor lesion. J Pathol Clin Res (2017) 0.75
Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia. Ann Lab Med (2017) 0.75
Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers. J Korean Med Sci (2017) 0.75
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget (2017) 0.75
NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. Oncotarget (2016) 0.75
Highly sensitive, non-invasive detection of colorectal cancer mutations using single molecule, third generation sequencing. Appl Transl Genom (2015) 0.75
Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature. J Neurooncol (2015) 0.75
Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors. Neoplasia (2017) 0.75
Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform. J Cancer (2017) 0.75
Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing. Oncotarget (2017) 0.75
Managing the genomic revolution in cancer diagnostics. Virchows Arch (2017) 0.75
Detection of false positive mutations in BRCA gene by next generation sequencing. Fam Cancer (2016) 0.75
Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One (2017) 0.75
A model of molecular interactions on short oligonucleotide microarrays. Nat Biotechnol (2003) 9.98
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
NFKBIA deletion in glioblastomas. N Engl J Med (2010) 3.96
Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol (2006) 3.76
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
Leukemia cutis. Am J Clin Pathol (2008) 3.38
FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res (2006) 3.28
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol (2007) 3.13
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res (2005) 3.10
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer (2004) 3.05
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol (2013) 3.04
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol (2010) 2.82
Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res (2006) 2.70
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) 2.63
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 2.62
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
Rapid and accurate identification of mycobacteria by sequencing hypervariable regions of the 16S ribosomal RNA gene. Am J Clin Pathol (2002) 2.48
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev (2011) 2.48
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol (2009) 2.36
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol (2012) 2.21
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer (2003) 2.21
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood (2009) 2.15
Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer (2004) 2.11
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer (2008) 2.07
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol (2014) 2.04
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol (2008) 1.99
Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene (2004) 1.95
Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol (2008) 1.94
Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing. Virchows Arch (2014) 1.93
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 1.91
Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg (2010) 1.85
Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol (2013) 1.84
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res (2006) 1.84
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
8p11 myeloproliferative syndrome: a review. Hum Pathol (2010) 1.81
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res (2005) 1.81
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma (2012) 1.80
Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc Natl Acad Sci U S A (2007) 1.78
VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol (2008) 1.77
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2011) 1.75
Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol (2008) 1.75
Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol (2010) 1.71
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol (2009) 1.69
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol (2013) 1.68
Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med (2012) 1.66
Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol (2006) 1.64
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol (2013) 1.63
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood (2009) 1.62
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res (2009) 1.61
Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma (2010) 1.61
Myeloid sarcoma involving the gynecologic tract: a report of 11 cases and review of the literature. Am J Clin Pathol (2006) 1.59
Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn (2012) 1.59
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res (2005) 1.57
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med (2003) 1.52
MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol (2009) 1.51
Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev (2009) 1.51
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia (2010) 1.51
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 1.50
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer (2003) 1.49
EBV-positive diffuse large B-cell lymphoma of the elderly. Blood (2013) 1.49
Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol (2008) 1.49